NAIL ADVERSE EFFECTS of Immunotherapy and Targeted Cancer Drugs

Paronychia and periungual pyogenic granulomas are the most common nail adverse effects observed with targeted drugs used in targeted cancer treatment and with immunotherapies. Important findings from an evidence-based literature review on this topic were published on July 21, 2021 in the Journal of the American Academy of Dermatology.
Note: Nail disorders are described in the table below.
Nail Adverse Effects of Cancer Treatments
Dr. Anisha B. Patel and colleagues from the Department of Dermatology at the University of Texas Anderson Cancer Center in Houston, who took part in the study, wrote:
“Dermatological adverse effects are often the earliest and most frequent adverse effects of targeted anticancer therapies and immunotherapies. Immunotherapy-related nail adverse effects are caused by nonspecific immune system activation. Targeted therapies, particularly mitogen-activated protein kinase pathway inhibitors, cause epidermal thinning in the nail folds and periungual tissue (around the nail), increasing susceptibility to trauma and penetration by fragments of the nail plate, as in ingrown nails. Although the skin adverse effects of cancer treatments are well described, nail adverse effects need further characterization.”
The researchers searched the PubMed database using the terms nail, nail toxicity, nail dystrophy, paronychia, onycholysis, pyogenic granuloma, onychopathy, targeted therapy and immunotherapy. They then reviewed articles for clinical presentations, diagnosis, frequency, outcomes and references.
What Are Nail Disorders?
|
Nail Dystrophy |
Disruption of normal nail plate structure and changes in its color. It can affect the nail matrix, nail bed and surrounding tissue. |
|
Paronychia |
A skin infection around the nail that develops when bacteria or fungi enter beneath the skin. |
|
Onycholysis |
Separation of a fingernail or toenail from the pink nail bed. The separation occurs gradually and is painless. |
|
Onychoschizia |
Also described as nail splitting, onychoschizia includes split, brittle, soft or thin nails. |
|
Pyogenic Granuloma |
Usually a small, red, oozing and bleeding lump that can grow. |
|
Lichen Planus |
A condition that can cause swelling and irritation of the skin, hair, nails and mucous membranes. |
|
Psoriasis |
A condition causing red, flaky, crusted patches of skin covered with silvery scales. |
|
Dermatomyositis |
A group of muscle diseases causing muscle inflammation and swelling, resulting in skin rashes. |
Petel and colleagues found paronychia and periungual pyogenic granulomas to be the most common nail adverse effects caused by targeted therapy. Damage to other anatomical nail regions also includes pigmentary and neoplastic changes, along with drug-induced or worsened lichen planus and psoriasis. Onycholysis, onychoschizia, paronychia, psoriasis, lichen planus and dermatomyositis have been reported beginning from the first week to several months after treatment with immune checkpoint inhibitors (immunotherapies).
According to United States National Cancer Institute criteria, treatment-related nail adverse effects include nail changes, discoloration, swelling, paronychia and infection. Nail loss, paronychia and infection can be graded up to 3, defined as ‘severe or medically significant but not life-threatening’, while the remaining nail toxicities can only be categorized as grade 1, defined as ‘mild’ and ‘intervention not indicated’. Citing an earlier study, the authors wrote that “high-grade toxicities have been reported, particularly with pan-fibroblast growth factor receptor inhibitors” .
This review includes treatment algorithms for paronychia, periungual pyogenic granuloma, nail lichen planus and psoriasis. The authors said: “Long-term effective, nonselective immunosuppressants are reserved for dose-limiting toxicities, given the already immunocompromised state of cancer patients and the unknown effects on cancer treatment. A dermatologist should consult the oncology physician before starting an immunomodulator or immunosuppressant”.
Petel and colleagues recommended trimming the onycholytic nail plate toward its attachment point to manage onycholysis (nail loss). “Partial avulsion (cutting) is used to treat a persistent abscess or painful bleeding. A Pseudomonas superinfection is treated with a topical antibiotic solution twice daily. Brittle nail syndrome is treated with emollients or application of polyureaurethane, a 16% nail solution or a water-soluble nail lacquer.” They also noted that biotin supplementation is not recommended.
Nail adverse effects are among the most common reasons cancer patients consult a dermatologist
When severe, these reactions often affect patients' quality of life. This study will be useful for all dermatologists caring for cancer patients. Its strengths also include concisely summarizing the most commonly observed conditions and providing a clear, practical algorithm for approaching these nail toxicities. In addition to targeted drugs and immunotherapy, we commonly see nail toxicities caused by chemotherapy, which was not evaluated in this article. Multidisciplinary assessment and dermatological attention are certainly helpful in making the correct diagnosis and promptly managing these conditions, helping patients continue their cancer treatment.
Sources
2. Bender A. M. and Cohen B. A. (2013). Nail Dystrophy. Science Direct: https://www.sciencedirect.com
3. Cobb C. and Kandola A. (21.12.2018). How to treat paronychia (an infected nail). Medical News Today: https://www.medicalnewstoday.com
4. (05.12.2018). Onycholysis. Harvard Health Publishing: https://www.health.harvard.edu
5. Brittle Splitting Nails. American Osteopathic College Of Dermatology: https://www.aocd.org
6. Pyogenic Granuloma. American Osteopathic College Of Dermatology: https://www.aocd.org
7. Lichen Planus. Mayo Clinic: https://www.mayoclinic.org
8. Psoriasis. NHS: https://www.nhs.uk
9. Dermatomyositis. Johns Hopkins Medicine: https://www.hopkinsmedicine.org
Was this article helpful?
Your feedback helps us improve our content.





Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.